Cognition president and CEO, Lisa Ricciardi, presented at the Life Sciences Virtual Investor Conference on March 13, 2025. In her presentation, Ms. Ricciardi reviewed plans to support the advancement of zervimesine (CT1812) in Alzheimer’s disease and dementia with Lewy bodies following the Company’s positive Phase 2 data readouts.
An archive of Lisa Ricciardi’s corporate presentation may be viewed by clicking here.
